INBP — INTEGRATED BIOPHARMA INC
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1016504 ·
Last close
$0.18
Market Cap
$5.59M
52W High
$0.42
52W Low
$0.14
ADV30
6,283
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 10,107,000 | -276,000 | -1,085,000 | -837,000 | 26,669,000 | 5,826,000 | 7,687,000 |
| Dec 2025 | 11,280,000 | 29,000 | -914,000 | -762,000 | 23,547,000 | 5,314,000 | 3,779,000 |
| Sep 2025 | 12,689,000 | 1,019,000 | 163,000 | 123,000 | 25,540,000 | 4,732,000 | 5,051,000 |
| Jun 2025 | 14,175,000 | 1,469,000 | 589,000 | -178,000 | 24,901,000 | 3,615,000 | 4,584,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$3,026,000
Investing CF
$-195,000
Financing CF
$34,000
CapEx
$-317,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.07
As of
2026-09-27
Balance + Analyst (yfinance extras)
Retained Earnings
$-32,895,000
Inventory
$8,119,000
Receivables
$3,655,000
ST Investments
—
EBIT TTM
$-1,247,000
Pretax Income TTM
$-1,118,000
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$43,872,000
EBITDA
$-2,412,000
Free Cash Flow
$2,798,625
Enterprise Value
$4,312,650
Total Cash
$4,471,000
Total Debt
$3,078,000
Shares Out
31,059,610
Trailing EPS
$-0.09
Book Value
$0.61
ROE
-15.0%
ROA
-6.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 54,353,000 | 2,020,000 | 808,000 | 24,901,000 | 4,584,000 | 20,317,000 | 2,065,000 |
| Jun 2024 | 50,317,000 | 251,000 | 112,000 | 26,207,000 | 6,969,000 | 19,238,000 | 943,000 |
| Jun 2023 | 50,672,000 | 120,000 | -34,000 | 25,431,000 | 6,570,000 | 18,861,000 | 1,232,000 |
| Jun 2022 | 56,246,000 | 2,745,000 | 3,838,000 | 25,250,000 | 6,675,000 | 18,575,000 | 4,091,000 |
TTM Snapshot
Revenues TTM
$33,207,000
NetIncome TTM
$-1,826,000
OpCashFlow TTM
$0
Assets (Latest)
$11,623,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XBIO | Xenetic Biosciences, Inc. | $5.60M | $2.39 | — |
| DRMA | Dermata Therapeutics, Inc. | $5.65M | $1.14 | — |
| XTLB | XTL BIOPHARMACEUTICALS LTD | $5.41M | $2.20 | — |
| KAPA | Kairos Pharma, LTD. | $5.82M | $1.72 | — |
| ACXP | Acurx Pharmaceuticals, Inc. | $5.84M | $1.36 | — |
News headlines (Yahoo Finance, 1h cache)
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026
2026-09-25 21:00 · Yahoo
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026
2026-05-08 20:30 · Yahoo
Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025
2026-02-11 21:30 · Yahoo
Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025
2025-11-10 20:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.